These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19500018)

  • 1. Deglycosylation or partial removal of HIV-1 CN54 gp140 V1/V2 domain enhances env-specific T cells.
    Wan Y; Liu L; Wu L; Huang X; Ma L; Xu J
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):607-17. PubMed ID: 19500018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines.
    Liu L; Wan Y; Xu J; Huang X; Wu L; Liu Y; Shao Y
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1396-404. PubMed ID: 18184083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade.
    Zhang C; Wan Y; Shi J; Zhou M; Meng Z; Yuan S; Qiu C; Zhang X; Xu X; Liu C; Xu J
    AIDS Res Hum Retroviruses; 2010 May; 26(5):569-75. PubMed ID: 20455767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.
    Wan Y; Wu L; Liu L; Xu J; Liu Y; Liu Y; Shao Y
    Vaccine; 2007 Jun; 25(26):4949-59. PubMed ID: 17350736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.
    Liu L; Hao Y; Luo Z; Huang Y; Hu X; Liu Y; Shao Y
    Vaccine; 2012 Jun; 30(28):4135-43. PubMed ID: 22561314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Fu M; Hu K; Hu H; Ni F; Du T; Shattock RJ; Hu Q
    Vaccine; 2019 Dec; 37(51):7501-7508. PubMed ID: 31564450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model.
    Dzhivhuho GA; Rehrl SA; Ndlovu H; Horsnell WGC; Brombacher F; Williamson AL; Chege GK
    PLoS Pathog; 2018 Jul; 14(7):e1007182. PubMed ID: 30048550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.
    Weaver EA; Camacho ZT; Gao F
    AIDS Res Hum Retroviruses; 2010 May; 26(5):577-84. PubMed ID: 20438382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
    Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
    AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
    Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
    Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
    DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunogenicities and comparison of DNA vaccines encoding pol genes derived from B`/C and A/E recombinant HIV-1 strains].
    Wan YM; Ren YQ; Wang J; Ren XN; Hu ZD; Qiu C; Xu JQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):551-5. PubMed ID: 22943905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
    Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
    Front Immunol; 2019; 10():2941. PubMed ID: 31921191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.